Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics

Int J Mol Sci. 2022 May 24;23(11):5881. doi: 10.3390/ijms23115881.

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs (18-24 nucleotides) that play significant roles in cell proliferation, development, invasion, cancer development, cancer progression, and anti-cancer drug resistance. miRNAs target multiple genes and play diverse roles. miRNAs can bind to the 3'UTR of target genes and inhibit translation or promote the degradation of target genes. miR-200 family miRNAs mostly act as tumor suppressors and are commonly decreased in cancer. The miR-200 family has been reported as a valuable diagnostic and prognostic marker. This review discusses the clinical value of the miR-200 family, focusing on the role of the miR-200 family in the development of cancer and anti-cancer drug resistance. This review also provides an overview of the factors that regulate the expression of the miR-200 family, targets of miR-200 family miRNAs, and the mechanism of anti-cancer drug resistance regulated by the miR-200 family.

Keywords: PD-L1; anti-cancer drug resistance; cancer/testis antigen CAGE; clinical value; mechanism; microRNA 200 family; microRNA mimics; molecular network.

Publication types

  • Review

MeSH terms

  • 3' Untranslated Regions
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Cell Line, Tumor
  • Cell Proliferation
  • Gene Expression Regulation, Neoplastic
  • Humans
  • MicroRNAs* / metabolism
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Neoplasms* / pathology

Substances

  • 3' Untranslated Regions
  • Antineoplastic Agents
  • MIRN200 microRNA, human
  • MicroRNAs